Sanofi and Regeneron Announce 18Month Results of ODYSSEY LONG TERM Trial with...
PARIS and TARRYTOWN N.Y. March 15 2015 PRNewswire &160;Sanofi and Regeneron Pharmaceuticals Inc. today announced that 18month 78week results of a Phase 3 trial of Praluent&8482; alirocumab an...
View ArticleAmgen Publishes Safety Analysis Of Investigational CholesterolLowering...
THOUSAND OAKS Calif. March 15 2015 PRNewswire &160;Amgen NASDAQ AMGN today announced oneyear data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase 2 OSLER1...
View ArticleSanofi Regeneron 18Month Results of ODYSSEY LONG TERM Trial with PraluentTM...
Sanofi and Regeneron Announce 18Month Results of ODYSSEY LONG TERM Trial with Praluent TM alirocumab Published in The New England Journal of Medicine Robust and consistent LDLC lowering demonstrated...
View ArticleRx Statin Critic Predicts Safer Use In LowerDose Switch OTCs
Duane Graveline says drug firms are going to realize they will not get any support from people who understand the full range of statin adverse effects. Tens of thousands of statin users report weakness...
View ArticleWe are overprescribing statin medications for high cholesterol. Heres why.
The American Heart Association AHAÂrecently proposed new guidelines for all doctors to screen and treat for high cholesterol. For doctors and patients to follow this would result in a large increase in...
View ArticleSynthetic Biologics Reports Year End 2014 Financial Results and Operational...
ROCKVILLE Md. March 16 2015 PRNewswire &160;Synthetic Biologics Inc. NYSE MKT SYN a developer of pathogenspecific therapies for serious infections and diseases with a focus on protecting the...
View ArticleSurvey finds doctors want to learn more about diet and cardiovascular disease...
Most physicians are aware of the importance of lifestyle factors in preventing cardiovascular disease CVDand believe diet is as important as statin therapy and exercise according to a new survey from...
View ArticlePhysicians want to learn more about diet cardiovascular disease prevention
Most physicians are aware of the importance of lifestyle factors in preventing cardiovascular disease CVD and believe diet is as important as statin therapy and exercise according to a new survey.
View ArticleSurvey Finds Physicians Want To Learn More About Diet And Cardiovascular...
NEW YORK March 16 2015 PRNewswireUSNewswire Most physicians are aware of the importance of lifestyle factors in preventing cardiovascular disease CVD and believe diet is as important as statin therapy...
View ArticleNew Analysis from Investigational IMPROVEIT Study Shows VYTORINÂ...
Merck NYSEMRK known as MSD outside the United States and Canada today announced results from a prespecified exploratory analysis of the investigational IMPROVEIT study of more than 18000 patients...
View ArticleEsperion Therapeutics Announces Positive TopLine Phase 2b Results for ETC1002...
ANN ARBOR MIMarketwired March 17 2015 Esperion Therapeutics Inc. NASDAQ ESPR an emerging pharmaceutical company focused on developing and commercializing firstinclass oral lowdensity lipoprotein...
View ArticleHormones with statins may help women's hearts after menopause
Hormones may not protect women from heart disease or stroke after menopause but when combined with cholesterollowering statin drugs they may help protect women from these killers shows a population...
View ArticleEsperion Therapeutics ESPR Releases TopLine Study009 Results
Esperion keeps reaching new highs and yesterday was no exception. Given the recent briefing by CEO Tim Mayleben and also Paul Thompson Study 008 principal investigator this isnt a surprise. Today...
View ArticleFinnish study explores association between statin use and diabetes
Researchers have shown that statin use increases the risk of type 2 diabetes and suggest that the higher risk is due to decreases in insulin sensitivity and insulin secretion.
View ArticleEsperion Therapeutics Announces Positive Phase 2b Results In Patients with...
Shares of Esperion Therapeutics ESPR are up about 22 after the company reported positive phase 2b results in Hypercholesterolemia. Esperion is using its own drug ECT1002 which is given to patients in...
View ArticleEsperion hits record high on ETC1002 results
Shares of Esperion Therapeutics Inc. NASDAQESPR jumped $22.50 29 to $99.60 hitting an alltime high on Tuesday after the company said ETC1002 met the primary endpoint of lowering LDLcholesterol vs....
View ArticleMedical News Today Statin drug rosuvastatin 'does not deserve' bestselling slot
Rosuvastatin has been lambasted in The BMJ by a doctor working for consumer group Public Citizen and he hopes the statin's sales 'decline' for 'the sake of public's health.'
View ArticleEsperion surges on Phase IIb cholesterollowering data
Esperion Therapeutics jumped 29.2 to a new alltime high of $99.60 per share on 17 March after the company reported that ETC1002 lowered LDL cholesterol by up to 24 in combination with a low to...
View ArticleAfter the Financing Announcement Our Thoughts on Esperion's Strategy
Soon after yesterday's wonderful clinical news Esperion announced a public offering and filed a prospectus."..it intends to offer and sell subject to market and other conditions $150 million of its...
View ArticleSynthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a...
ROCKVILLE Md. March 19 2015 PRNewswire Synthetic Biologics Inc. NYSE MKT SYN a developer of pathogenspecific therapies for serious infections and diseases with a focus on protecting the microbiome...
View Article